Konica Minolta, Inc. (the “Company”) announced on November 5, 2024, in “Notice Regarding Change in a Consolidated Subsidiary (Transfer of Share) and Recording of Profit from Discontinued Operations due to the Share Transfer,” that it had transferred all shares of Ambry Genetics Corporation to Tempus AI, Inc. (“Tempus”). As consideration for the transfer, the Company received total consideration of US$600 million in the fiscal year ended March 31, 2025, consisting of US$375 million in cash and Tempus stock valued at US$225 million.

The Tempus stock acquired was subject to contractual restrictions, and the Company began selling it in stages from the first quarter of the fiscal year ended March 31, 2026. The Company has now completed the sale of all Tempus stock it held in the first quarter of the fiscal year ending March 31, 2027.

The amount of the sale of Tempus stock executed in the first quarter of the fiscal year ending March 31, 2027, was 15.9 billion yen. The proceeds obtained from the sale are planned to be used for the reduction of interest-bearing debt and shareholder returns, among other purposes, in order to strengthen the Company’s financial structure and improve capital efficiency. In addition, the Company expects to record a profit of 2.9 billion yen from discontinued operations in the same quarter in connection with the sale.